Barry Seibel, MD
Ophthalmology · Los Angeles, CANPI 1992719124
Payments from drug & device makers
Across 357 payments — averaging $2338.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Katena Products, Inc. (dba Corza Medical)$301K
- Carl Zeiss Meditec, Inc.$199K
- Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$137K
- Bausch & Lomb Americas Inc.$75K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$72K
- Johnson & Johnson$37K
- plus $14K from 21 others
Across 1 payment — averaging $5210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$5K
What the payments were for
- Royalty or licence$319,07538%
- Consulting fees$261,90031%
- Speaking & faculty fees$191,11623%
- Travel & lodging$53,0726%
- Food & beverage$9,6571%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Katena Products, Inc. (dba Corza Medical) | 23 | $300,804 |
| Carl Zeiss Meditec, Inc. | 35 | $198,555 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 16 | $137,481 |
| Bausch & Lomb Americas Inc. | 97 | $75,175 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 101 | $71,963 |
| Johnson & Johnson | 4 | $36,841 |
| Alcon | 12 | $5,592 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $4,087 |
| Lensar, Inc. | 2 | $1,348 |
| Carl Zeiss Meditec USA, Inc. | 8 | $1,171 |
| Carl Zeiss Meditec Cataract Technology Inc. | 3 | $275 |
| Novartis | 11 | $248 |
| Amgen | 9 | $206 |
| Oyster Point Pharma, Inc. | 4 | $179 |
| Kala Pharmaceuticals, Inc. | 4 | $163 |
| Omeros Corporation | 3 | $147 |
| Sun Pharmaceutical Industries Inc. | 5 | $146 |
| Shire North American Group Inc | 1 | $125 |
| Tarsus Pharmaceuticals, Inc. | 3 | $95 |
| Rxsight Inc | 3 | $56 |
| Glaukos Corporation | 2 | $38 |
| AbbVie | 2 | $37 |
| Dompe US, Inc. | 1 | $34 |
| Biotissue Holdings Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $17 |
| Harrow Eye, LLC | 1 | $17 |
| Auris Health, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$67,421
- OPHTHALMIC INSTRUMENTS$62,802
- katena$62,166
- Surgical instrument$57,826
- IOLMaster 700$53,900
- VisuMax$42,643
- CLARUS$39,433
- MIEBO$29,922
- XIIDRA$26,680
- FORUM Glaucoma Workplace$25,105
- CLARUS 500 Fundus Camera$23,611
- STELLARIS$21,621
- Humphrey HFA$21,335
- QUATERA 700$18,297
- ENVISTA$17,081
- FORUM$15,970
- CIRRUS 6000 with AngioPlex$15,225
- enVista MX60 IOL$14,096
- Crystalens Accommodating IOL (AT-52AO)$13,947
- Trulign IOL$13,947
How this compares
$834,821 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lotemax SmLoteprednol Etabonate | 149 | $37,074 |
| ProlensaBromfenac Sodium | 94 | $32,103 |
| RestasisCyclosporine | 32 | $29,924 |
| BesivanceBesifloxacin Hcl | 121 | $26,522 |
| XiidraLifitegrast | 22 | $14,813 |
| MieboPerfluorohexyloctane/Pf | 12 | $9,031 |
| LumiganBimatoprost | 27 | $8,932 |
| Restasis MultidoseCyclosporine | 12 | $7,620 |
| VyzultaLatanoprostene Bunod | 18 | $5,191 |
| MoxifloxacinMoxifloxacin Hcl | 191 | $3,779 |
| Bromfenac Sodium | 16 | $3,122 |
| Loteprednol Etabonate | 25 | $2,865 |
| Cosopt PfDorzolamide/Timolol/Pf | 13 | $2,441 |
| Prednisolone Acetate | 68 | $2,175 |
| Ketorolac Tromethamine | 46 | $666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Besivance, Loteprednol Etabonate | $71,963 | $98,563389 claims |
| AbbVieRestasis, Lumigan, Restasis Multidose | $37 | $46,47771 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $75,175 | $29,03552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Steven JacobsonLos Angeles$4.7M
- David BoyerLos Angeles$4M
- Firas RahhalLos Angeles$1.2M
- Nicole FramLos Angeles$1.2M
- Andrew MoshfeghiLos Angeles$1M
- Pradeep PrasadLos Angeles$901K
- David LiaoLos Angeles$722K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.